not been studied for the treatment of tinnitus. We therefore compared the effect of i.v. ropivacaine with that of lidocaine for the treatment of tinnitus.
Methods
Twenty patients suffering from tinnitus were recruited from the audiology department of Helsinki University Hospital. The study was approved by the Ethics Committee of the hospital and the National Agency for Medicines, and the patient volunteers gave their written informed consent. They all had moderate or severe tinnitus that had lasted on an average for 124 months (range, 12-360 months). To be eligible, they had to be otherwise in good health with no neurological or cardiac disease. One patient had medication for high arterial pressure. The patient characteristics are presented in Table 1 . All subjects had audiometry and otoacoustic emissions done before the infusion. The most common causes of the tinnitus were noise trauma (n¼8) and sensorineural hearing loss (n¼6).
A randomized (sealed envelopes), double-blind, crossover design was followed for the study, and a total dose of 1.5 mg kg 21 of lidocaine or ropivacaine was given i.v. over 30 min with an infusion pump (Perfusor w Space, B. Braun Melsungen, Germany). The dose (1.5 mg ml 21 ) of lidocaine was the same as that has been generally used in studies on the treatment of tinnitus. 7 8 As there are no published studies on the use of i.v. ropivacaine for the treatment of tinnitus, we chose the same dose as used for lidocaine, considering that comparable doses up to a maximum of 150 mg i.v. have been administered safely in volunteers, 10 -12 and a dose of 2 mg kg 21 i.v. has been found not to be ototoxic in rabbits. 13 The infusions were given into a peripheral vein by an anaesthesiologist and a nurse in the post-anaesthesia care unit of the university ear -nose -throat hospital. All of the infusions were started at 3 -4 p.m. Monitoring during infusion and 1 h thereafter included ECG, non-invasive arterial pressure, and pulse oximetry. The time interval between the two infusions was 2 -3 months.
We used self-evaluating scores of the tinnitus handicap inventory (THI, 0 -100, higher number for greater handicap) 14 to evaluate the handicap of tinnitus and reported scores on visual analogue scale (VAS, 0 indicating no tinnitus, 10 indicating the worst imaginable degree of tinnitus) to evaluate its intensity. A 30% reduction on the THI scale and a 50% reduction in VAS scores were considered clinically significant. THI and VAS scores were evaluated immediately before the infusion, at 9 p.m. on the evening of the infusion day (about 4 h after the treatment) and thereafter on Days 1, 3, and 5, and weekly until 4 weeks after the infusion. In addition, VAS score was recorded immediately and 1 h after the infusion. The patients returned their THI evaluation sheets by mail.
The cubital vein opposite to the arm of the infusion was cannulated for timed blood samples, and 10 ml of blood sample was obtained before the infusion, 15 min after the start and at the end of infusion (30 min after the start), and 30 and 60 min after the end of the infusion into 10 ml EDTA tubes (Venoject w , Terumo Europe NV, Leuven, Belgium). The blood samples were centrifuged within 2 h and plasma was separated and stored at 2708C until analysed. Lidocaine and ropivacaine plasma concentrations were assayed by liquid chromatography. 15 The quantification limit for both was 1 ng ml 21 . The intra-day 
Results
The characteristics of the patients and their tinnitus symptoms are shown in Table 1 . Fourteen patients had documented hearing loss in audiometry and 13 of them had deviant responses in otoacoustic emissions. The occurrence of hearing loss or presence of spontaneous emissions did not predict the relief of tinnitus by the local anaesthetic treatment. One patient (no. 12) was unwilling to continue in the study after the first treatment session (ropivacaine) during which she had some numbness of the upper extremities. Her VAS values and local anaesthetic concentrations from that session are included in the analyses. Thus, complete data sets were obtained from 19 patients.
Immediately after six infusion sessions (five ropivacaine and one lidocaine), marked relief (DVAS50%) of tinnitus was seen. This degree of relief was sustained for .1 h after two ropivacaine treatments. In three patients, the tinnitus VAS score was temporarily increased by 30% at the end of ropivacaine infusion, when their plasma ropivacaine concentrations were 2216 -2679 ng ml 21 . Significantly less tinnitus (VAS score) was reported 1 h after ropivacaine treatment in comparison with the score 1 h after lidocaine treatment (P¼0.048, Wilcoxon's test). Four weeks after ropivacaine treatment, patients reported significantly more tinnitus than 1 or 4 h after ropivacaine treatment (P¼0.003, Friedman's test). At other time points, the intensity of tinnitus (VAS or THI) did not differ significantly between or within the ropivacaine and lidocaine treatments ( Table 2, Figs 1 and 2) . Only one patient after ropivacaine infusion and two after lidocaine infusion had .30% reduction in the THI after 4 weeks.
One patient (no. 11, male 100 kg) lost his consciousness and developed tonic-clonic convulsive activity in his extremities a few minutes after the completion of ropivacaine (150 mg) infusion, soon after the 30 min venous blood sampling. He was ventilated by mask using 100% O 2 , and the convulsions were abolished with diazepam 5 mg i.v. repeated four times. He had no oxygen desaturation and his cardiovascular variables remained stable. He recovered in 10 min and was rather tired with moderate numbness of all extremities. There were no significant changes in the intensity of his tinnitus, other than that a distinct lower frequency sound had ceased. In the second infusion with lidocaine 150 mg about 2 months later, this patient experienced no adverse effects and no effect on tinnitus, either.
Seven patients after ropivacaine and four after lidocaine experienced tiredness after the end of the infusion. Five patients after ropivacaine infusion, including the one with convulsions, had temporary numbness in different parts of the body, one in the area surrounding the mouth. Lidocaine infusion caused numbness of the upper extremities in two patients. In the telephone interview on the following day, five patients after ropivacaine infusion and two after lidocaine infusion complained of dizziness.
The total plasma concentrations of ropivacaine and lidocaine are shown in Figures 3 and 4 . In general, the highest concentration of both drugs was observed at the end of infusion. However, the decline after the infusion was markedly faster with lidocaine. The highest individual Table 2 Visual analogue scale (VAS) and tinnitus handicap inventory (THI) scores of tinnitus (a few missing values), measured before and after the infusion of ropivacaine or lidocaine 1.5 mg kg 21 . Delta (D) values (comparisons with scores before infusion). Percentages of patients with more than 50% decrease in VAS score and more than 30% decrease of THI. Some clinically insignificant differences occurred in VAS scores (*P¼0.048 with Wilcoxon's test, †, ‡
P¼0.003 with Friedman's test). THI scores did not differ significantly between or within the treatments

Time
Median (range) of VAS (0 -10), median D, % of patients with DVAS50%
Median (range) of THI (0-100), median D, % of patients with DTHI30%
Ropivacaine Lidocaine Ropivacaine Lidocaine ropivacaine concentration was 3483 ng ml 21 (no. 15, male 103 kg). He had no adverse effects and the intensity of tinnitus stayed stable (VAS score 6). The highest individual concentration of lidocaine was 1680 ng ml 21 , in a patient (no. 1, male 97 kg), who obtained a temporary reduction in the intensity of tinnitus (baseline VAS score 2 and after infusion VAS score 1) without adverse effects.
The plasma concentrations of ropivacaine declined slowly (Fig. 3) . For instance, in patient with convulsions, the concentration of ropivacaine 30 min after the infusion (1890 ng ml 21 ) was still at the same level as at the time of the end of infusion (1817 ng ml
21
). Still 1 h after infusion, the concentration (1493 ng ml
) had not declined very much. In another patient (no. 18; male, 98 kg), circumoral numbness and difficulty in talking was associated with a high plasma ropivacaine concentration (3128 ng ml 21 ). His tinnitus was ameliorated at the end of infusion to be returned to the level before infusion in 1 h (VAS scores 5 -2-4).
Discussion
Previously reported, occasional long-lasting effects by lidocaine on tinnitus were also seen in the present study. 6 -8 However, a 30 min infusion of ropivacaine or lidocaine in a dose of 1.5 mg kg 21 had no long-lasting significant effect on tinnitus. A clinically significant reduction in the intensity of tinnitus occurred only in a few patients at the end of infusion, or 60 min later.
Clinically, lidocaine has been used as an antiarrhythmic in ventricular dysrhythmias, 16 as an anticonvulsant for the treatment of epileptic seizures 17 and occasionally for the treatment of neuropathic pain 18 and various types of severe headache. 19 20 Independent of the targeted i.v. therapy, there is always a risk of systemic toxicity. 21 The popularity of lidocaine for the therapy of cardiac and neurological disorders has been based on its relatively wide therapeutic window (dose/concentration producing wanted effect vs dose/concentration producing systemic toxicity). In spite of similar local anaesthetic mechanisms of action, ropivacaine has not been shown to be therapeutically applicable in any of the situations mentioned above. The reason for this is its significantly greater anaesthetic potency and systemic toxicity compared with lidocaine 22 making it very difficult to titrate safe dose without toxicity. In fact, in our study, we encountered one possible case of pre-toxic symptoms (circumoral numbness) after having infused 147 mg of ropivacaine in a 98 kg patient, and one obvious systemic toxicity reaction (seizures) after having infused 150 mg of ropivacaine in a 100 kg patient. The ropivacaine concentration in plasma in the former patient (3128 ng ml 21 ) was the second highest individual value. However, considering that the free fraction of ropivacaine in plasma is usually approximately 5%, the extrapolated unbound ropivacaine concentration would be 156 ng ml 21 , which is less than half of the level shown to result in mild toxic symptoms in healthy volunteers. 11 In the latter patient, the ropivacaine plasma concentration (1817 ng ml
21
) in the blood sample obtained immediately before the start of the seizures was not excessively high, suggesting that there may be large interindividual differences between seizure threshold among patients and, perhaps, among patients with concomitant neural disturbance (tinnitus). The plasma ropivacaine concentration 30 min after the end of infusion was still at the same level as or even slightly higher than at the end of infusion. This suggested slow clearance and an unusual redistribution of ropivacaine during convulsions and initial recovery.
In conclusion, the efficacy of i.v. ropivacaine and lidocaine 1.5 mg kg 21 in the treatment of tinnitus is weak, short lasting, and occasional. I.V. ropivacaine 1.5 mg kg 21 infused in 30 min is not suitable for the treatment of tinnitus. One case of clear systemic toxicity (seizures) and another of mild pre-toxic symptoms after ropivacaine treatment further support our view. A clinically significant, temporary effect by i.v. lidocaine on tinnitus was observed only in a few patients but its safety was better than that of ropivacaine.
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